^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + eganelisib (IPI-549) (PI3Kγ inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium
Published date:
02/11/2021
Excerpt:
Infinity Pharmaceuticals, Inc...today presented data from MARIO-275 (MAcrophage Reprogramming in Immune Oncology), a randomized, placebo-controlled Phase 2 study evaluating the efficacy and safety of eganelisib in combination with nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced urothelial cancer (UC)...Greatest benefit of eganelisib with nivolumab combination therapy over nivolumab monotherapy was observed in the PD-L1 negative patient population (n=23) with improvement over nivolumab monotherapy (n=7) for overall response rate (ORR) (26% vs. 14%); disease control rate (DCR) (57% vs. 14%); and best responses of complete response (CR) (9% vs. 0%), and stable disease (SD) (30% vs. 0%)...
Trial ID:
